CD44 and pleural mesothelioma: Upon intrapleural administration of these bio-nanocarriers at a dose of 1.5 mg kg−1 Cisplatin in an orthotopic mice model of pleural mesothelioma, the bio-nanocarriers demonstrated significantly higher CD44 expression and subsequently synergistic cellular uptake of Cisplatin in the mesothelioma cells [297].